BLACKMORES LIMITED (BKL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BKL - BLACKMORES LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Household & Personal Products
Index: ASX200 | ASX300 | ALL-ORDS

Blackmores is Australia's leading natural health supplement company manufacturing and marketing a range of food supplements, including vitamins, mineral and herb products. Founded in 1932, it became a public company in 1985.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$70.92

05 Dec
2022

0.450

OPEN

$71.00

0.64%

HIGH

$71.51

11,348

LOW

$70.07

TARGET
$74.05 4.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
EBO . MCP . API . EXL . SIG . CLV .
FNARENA'S MARKET CONSENSUS FORECASTS
BKL: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx 157.9 213.7 xxx
DPS (cps) xxx 95.0 129.1 xxx
EPS Growth xxx 22.9% 35.3% xxx
DPS Growth xxx 33.8% 35.9% xxx
PE Ratio xxx N/A 33.2 xxx
Dividend Yield xxx N/A 1.8% xxx
Div Pay Ratio(%) xxx 60.2% 60.4% xxx

Dividend yield today if purchased 3 years ago: 1.18%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.35

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 31/08 - ex-div 32c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx157.9
DPS All xxxxxxxxxxxxxxx95.0
Sales/Revenue xxxxxxxxxxxxxxx649.5 M
Book Value Per Share xxxxxxxxxxxxxxx2,040.8
Net Operating Cash Flow xxxxxxxxxxxxxxx48.5 M
Net Profit Margin xxxxxxxxxxxxxxx4.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx7.96 %
Return on Invested Capital xxxxxxxxxxxxxxx7.57 %
Return on Assets xxxxxxxxxxxxxxx5.32 %
Return on Equity xxxxxxxxxxxxxxx7.96 %
Return on Total Capital xxxxxxxxxxxxxxx13.07 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx22.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

19/08/2022

1

Upgrade to Outperform from Neutral

$90.00

26.90%

Blackmores' result missed Credit Suisse on out-of-stocks in Australia, China lockdowns, restoration of incentive payments and difficult to measure inflationary pressure.

But the broker upgrades to Outperform on the basis that upside risk is greater than downside, suggesting that through price
increases and cost savings, Blackmores has the chance to pull growth forward.

One key challenge in FY23 is the company will be cycling tough covid comparables for immunity products, particularly in Indonesia in the September quarter. Target unchanged at $90.

FORECAST
Credit Suisse forecasts a full year FY23 dividend of 139.00 cents and EPS of 232.00 cents.
Credit Suisse forecasts a full year FY24 dividend of 161.00 cents and EPS of 268.00 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

BKL STOCK CHART

FNArena News on BKL

1
Australian Broker Call *Extra* Edition – Sep 21, 2022

Sep 21 2022 - Daily Market Reports
2
Rudi’s View: August Delivering More Downgrades And Misses

Aug 25 2022 - Rudi's View
3
Weekly Ratings, Targets, Forecast Changes – 19-08-22

Aug 22 2022 - Weekly Reports
4
FNArena Corporate Results Monitor – 19-08-2022

Aug 19 2022 - Australia
5
Rudi’s Views: Pre-August Observations

Jul 21 2022 - Rudi's View

Latest Health & Nutrition News

1
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
2
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
3
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
4
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
5
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
6
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
7
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
8
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
9
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
10
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia